Head-To-Head Comparison: VYNE Therapeutics (NASDAQ:VYNE) & Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL) and VYNE Therapeutics (NASDAQ:VYNE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Insider & Institutional Ownership

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Madrigal Pharmaceuticals and VYNE Therapeutics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	N/A	N/A	-$373.63 million	($19.94)	-11.53
VYNE Therapeutics	$420,000.00	87.96	-$28.45 million	($7.04)	-0.37

VYNE Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Madrigal Pharmaceuticals has a beta of -0.33, indicating that its share price is 133% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Profitability

This table compares Madrigal Pharmaceuticals and VYNE Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	N/A	-219.39%	-98.75%
VYNE Therapeutics	-6,710.38%	-77.46%	-62.93%

Analyst Recommendations

This is a breakdown of current recommendations for Madrigal Pharmaceuticals and VYNE Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	1	9	0	2.73
VYNE Therapeutics	0	0	1	0	3.00

Madrigal Pharmaceuticals presently has a consensus price target of $356.73, suggesting a potential upside of 55.21%. VYNE Therapeutics has a consensus price target of $7.38, suggesting a potential upside of 181.49%. Given VYNE Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe VYNE Therapeutics is more favorable than Madrigal Pharmaceuticals.

Summary

VYNE Therapeutics beats Madrigal Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About VYNE Therapeutics

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.